Skip to main content
Caplight Logo









SkylineDx

SkylineDx

Private
RotterdamHealthcare & Life Scienceshttps://www.skylinedx.com/

Last Round

Grant

Dec 11, 2023

Momentum

Top 10%

of companies Caplight tracks

Company Overview

SkylineDx is a biotechnology company that develops and commercializes gene signature-based diagnostic tests to assist healthcare professionals in personalized treatment decision-making.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Precision Medicine, Healthcare Analytics

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Application

Keywords

molecular diagnosticsoncology diagnosticsgenomic testingmelanoma testgene expression profilingpredictive algorithmsdiagnostic AIpersonalized medicinemultiple myeloma testcancer genomicsclinical decision supportrisk stratificationlab developed testLDTbiomarker discoveryCAP/CLIA labtranslational medicine

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

SkylineDx Comparables

Compare SkylineDx with similar companies based on industry and business-model similarity.

SkylineDx comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
AMLo Biosciences
84%
NeraCare
80%
Castle Biosciences, Inc.
79%

SkylineDx Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantDec 11, 2023
VC RoundDec 21, 2021
VC RoundSep 2, 2019
GrantOct 4, 2016

SkylineDx Investors

Notable investors and investment history

SkylineDx investors
InvestorRounds
European CommissionGrant
Novalis LifeSciencesVC Round
VIBGrant
Stichting Van Herk InvestmentsVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Aug 21, 2026

    Monthly visitors grew 64% MoM, reaching 5.7K.

  • Apr 16, 2025

    Monthly visitors increased 74% MoM.

SkylineDx Filings

Explore SEC and related filing metadata, where available.

SkylineDx filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about SkylineDx's valuation, stock price, and market status.

Is SkylineDx a public or private company?

SkylineDx is a private company.

What is the current stock price of SkylineDx?

SkylineDx is a private company with no public stock price. No recent secondary market data is available.

How much is SkylineDx worth (valuation)?

Valuation information for SkylineDx is not publicly available.

Can I buy SkylineDx stock?

SkylineDx shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.

When was SkylineDx's last funding round?

SkylineDx's most recent funding round was Grant on December 11, 2023.

Who are the main investors in SkylineDx?

Key investors in SkylineDx include Novalis LifeSciences, Stichting Van Herk Investments.

Will SkylineDx IPO soon?

No public IPO plans have been announced for SkylineDx.

How can I track SkylineDx secondary market activity?

Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor SkylineDx's secondary market activity and sign up for updates.

Firmographic Details

HeadquartersRotterdam
Employee Range78
Year Founded2013
Last FundingDec 11, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?